FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

24684511000001103: Erlibelle 30microgram/150microgram tablets (Actavis UK Ltd) (product)


Status: current, Not sufficiently defined by necessary conditions definition status. Date: 23-Jul 2014. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
80152601000001114 Erlibelle 30microgram/150microgram tablets (Actavis UK Ltd) (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
80152701000001116 Erlibelle 30microgram/150microgram tablets (Actavis UK Ltd) en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module


0 descendants.

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
Erlibelle 30microgram/150microgram tablets (Actavis UK Ltd) Has excipient Excipient not declared true Inferred relationship Existential restriction modifier
Erlibelle 30microgram/150microgram tablets (Actavis UK Ltd) Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Erlibelle 30microgram/150microgram tablets (Actavis UK Ltd) Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction not available true Inferred relationship Existential restriction modifier
Erlibelle 30microgram/150microgram tablets (Actavis UK Ltd) Is a Product containing precisely ethinylestradiol 30 microgram and levonorgestrel 150 microgram/1 each conventional release oral tablet true Inferred relationship Existential restriction modifier
Erlibelle 30microgram/150microgram tablets (Actavis UK Ltd) Has active ingredient Ethinylestradiol false Inferred relationship Existential restriction modifier
Erlibelle 30microgram/150microgram tablets (Actavis UK Ltd) Has active ingredient Levonorgestrel false Inferred relationship Existential restriction modifier
Erlibelle 30microgram/150microgram tablets (Actavis UK Ltd) Has manufactured dose form Conventional release oral tablet true Inferred relationship Existential restriction modifier
Erlibelle 30microgram/150microgram tablets (Actavis UK Ltd) VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
Erlibelle 30microgram/150microgram tablets (Actavis UK Ltd) VMP non-availability indicator Available true Inferred relationship Existential restriction modifier
Erlibelle 30microgram/150microgram tablets (Actavis UK Ltd) Has specific active ingredient Ethinylestradiol true Inferred relationship Existential restriction modifier
Erlibelle 30microgram/150microgram tablets (Actavis UK Ltd) Has specific active ingredient Levonorgestrel true Inferred relationship Existential restriction modifier
Erlibelle 30microgram/150microgram tablets (Actavis UK Ltd) Has dispensed dose form Tablet true Inferred relationship Existential restriction modifier
Erlibelle 30microgram/150microgram tablets (Actavis UK Ltd) Has excipient Lactose false Inferred relationship Existential restriction modifier
Erlibelle 30microgram/150microgram tablets (Actavis UK Ltd) Is a Erlibelle true Inferred relationship Existential restriction modifier
Erlibelle 30microgram/150microgram tablets (Actavis UK Ltd) Is a Actual medicinal product true Inferred relationship Existential restriction modifier

Inbound Relationships Type Active Source Characteristic Refinability Group
Erlibelle 30microgram/150microgram tablets (Actavis UK Ltd) 63 tablet 3 x 21 tablets Has AMP True Erlibelle 30microgram/150microgram tablets (Actavis UK Ltd) Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start